

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Docket Number:
12961/46601

Application Number
10/532,836

Filing date
April 26, 2005

Examiner
NAGUBANDI

Art Unit
1621

Invention Title
**HIGHLY PURE BASES OF 3,3-
DIPHENYLPROPYLAMINO MONOESTERS**

Inventor(s)
Breitenbach et al.


Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date: February 21, 2007

By:



Joseph A. Coppola (Reg. No. 38,413)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed, however, in accordance 37 C.F.R. § 1.98 (a)(2)(ii), copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
4. The Commissioner is authorized to charge Kenyon & Kenyon LLP's Deposit Account No. 11-0600 for the 37 C.F.R. §1.17(p) fee of \$180.00 for filing this Information Disclosure Statement under 37 C.F.R. §1.97(c). The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Kenyon & Kenyon LLP's Deposit Account No. 11-0600. A duplicate of this communication is enclosed for charging purposes.

Respectfully submitted,


Dated: February 21, 2007

By:


Joseph A. Coppola (Reg. No. 38,413)

03/01/2007 AWONDAF1 00000001 110600 10532836
01 FC:1806 180.00 DA

KENYON & KENYON LLP
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT
Form PTO-1449**

ATTY. DOCKET NO. 12961/46601	APPLICATION NO. 10/532,836
APPLICANT Armin BREITENBACH et al.	
FILING DATE April 26, 2005	GROUP 1621

U. S. PATENT DOCUMENTS*

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	2,556,636	June 12, 1951	Nathan Sperber et al.			
	2,567,245	September 11, 1951	Nathan Sperber et al.			
	2,676,964	April 27, 1954	Nathan Sperber et al.			
	3,261,841	July 19, 1966	Bernard L. Zenitz			
	3,446,901	May 27, 1969	G. J. Macclesfield			
	4,988,730	January 29, 1991	Korbonits et al.			
	5,382,600	January 17, 1995	Jonsson et al.			
	5,559,269	September 24, 1996	Johansson et al.			
	5,922,914	July 13, 1999	Gage et al.			
	6,517,864	February 11, 2003	Orup Jacobsen et al.			
	6,310,248	October 30, 2001	Andersson et al.			
	6,566,537	May 20, 2003	Andersson et al.			
	6,630,162	October 7, 2003	Nilvebrant et al.			
	6,689,916	February 10, 2004	Andersson et al.			
	6,713,464	March 30, 2004	Meese et al.			
	6,770,295	August 3, 2004	Kreilgard et al.			
	6,783,769	August 31, 2004	Arth et al.			
	6,809,214	October 26, 2004	Meese			
	6,809,225	October 26, 2004	Donsbach et al.			
	6,858,650	February 22, 2005	Meese			
	6,890,920	May 10, 2005	Richards et al.			
	6,911,217	June 28, 2005	Gren et al.			
	2003/0124179	July 3, 2003	Jacobsen, Lene O. et al.			
	2004/0186061	September 23, 2004	Meese, Claus et al.			
	2005/0004223	January 6, 2005	Slatter, John G. et al.			
	2003/0152624	August 14, 2003	Aldrich et al.			
	2003/0158176	August 21, 2003	Richards et al.			
	2004/064821	April 1, 2004	Rousselle			

*- copies of U.S. references are not enclosed

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	925 468 (in German, with English translation)	March 21, 1955	DE			YES	
	1 216 318 (in German, with English translation)	May 12, 1966	DE			YES	
	325 571	July 26, 1989	EP				
	624 117	May 27, 1949	GB				
	627 139	July 29, 1949	GB				
	667 852	August 23, 1995	EP				
	685 696	January 07, 1953	GB				
	689 835	April 08, 1953	GB				
	690 274	April 15, 1953	GB				
	692 931	June 17, 1953	GB				
	766,207	December 22, 1952	DE			YES	
	831,799	June 7, 1996	EP				
	830,193	February 04, 1952	DE			YES	
	872,233	April 14, 1997	EP				
	948,321*	December 10, 1997	EP				
	957,073	May 12, 1998	EP				
	1 019 358	July 19, 2000	EP				
	1,025,041	February 24, 1964	GB				
	1 128 819	September 05, 2001	EP				
	1 169 944	November 05, 1969	GB				
	1 169 945	November 05, 1969	GB				
	WO 93/23025	November 25, 1993	PCT				
	WO 96/12477	May 02, 1996	PCT				
	WO 98/03067	January 29, 1998	PCT				
	WO 98/43942	October 8, 1998	PCT				
	WO 98/56359**	December 17, 1998	PCT				
	WO 00/12069	March 09, 2000	PCT				
	WO 00/27364	May 18, 2000	PCT				
	WO 01/34139	May 17, 2001	PCT				
	WO 02/089773	November 14, 2002	PCT				
	WO 02/11702	February 14, 2002	PCT				
	WO 03/002059	January 9, 2003	PCT				
	WO 03/007918	January 30, 2003	PCT				
	WO 03/020241	March 13, 2003	PCT				
	WO 03/026564	April 3, 2003	PCT				
	WO 03/035599	May 1, 2003	PCT				
	WO 03/039464	May 15, 2003	PCT				
	WO 03/063834	August 7, 2003	PCT				
	WO 03/099268**	December 4, 2003	PCT				
	WO 03/103637	December 18, 2003	PCT				
	WO 03/106421	December 24, 2003	PCT				

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	WO 03/021271	March 13, 2003	PCT			
	WO 04/019892	March 11, 2004	PCT			

*- English translation of claims provided

** - English translation of abstract provided

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Abrams et al., "Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder," 1998, Br. J. Urol. 81:801-810
		Abstracts from the 26 th Annual Meeting of the International Incontinence Society, August 27-30, 1996, Gillberg et al., abstract 33, Neurology and Urodynamics 15:308-309
		Anderson et al., "Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence," 1999, J. Urol. 161:1809-1812
		Andersson et al., "Pharmacological treatment of urinary incontinence," in Abrams P., Khoury S., Wein A. (Eds), <u>Incontinence, 2nd International Consultation on Incontinence</u> , Plymouth, Plymbridge Distributors Ltd, UK, Plymouth, 2002, pp 479-511
		Andersson, "Antimuscarinics for treatment of overactive bladder," 2004, Lancet Neurol. 3:46-53
		Andersson & Hedlund, "Pharmacological perspective on the physiology of the lower urinary tract," 2002, Urology 60(Suppl. 5A):13-20
		Andersson & Wein, "Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence," 2004, Pharmacol. Rev. 56:581-631
		Appell et al., "Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study," 2001, Mayo Clinic Proceedings 76:358-363
		Breidenbach et al., "Pharmacodynamic profiling of the novel antimuscarinic drug fesoterodine on rat bladder," 2002, Proceedings of the International Continence Society, 32:449
		Brynne et al., "Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine, 1998, Clin. Pharmacol. Thera. 63:529-539
		Brynne et al., "Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine, and omeprazole," 1999, Br. J. Clin. Pharmacol. 47:145-150
		Brynne et al., "Fluoxetine inhibits the metabolism of tolterodine – pharmacokinetic implications and proposed clinical relevance," 1999, Br. J. Clin. Pharmacol. 48:553-563
		Brynne et al., "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity," 1999, Br. J. Clin. Pharmacol. 48:564-572
		Cawello et al., "Multiple dose pharmacokinetics of fesoterodine in human subjects," 2002, Naunyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):428, 2002
		Chancellor et al., "A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate," 2001, Clinical Therapeutics 23:753-760
		Chapple & Udo, "Delay to maximum effect in overactive bladder patients treated with oxybutynin or tolterodine," 2000, European Urology 37(Suppl. 2):84, abstract 335 from the XVth Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000
		Chapple et al., "Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a Phase II controlled study," 2004, Proceedings of the International Continence Society, 34:142
		Clemett & Jarvis, "Tolterodine: a review of its use in the treatment of overactive bladder," 2001, Drugs & Aging 18:277-304
		Cole, "Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: A safety update," 2004, Drugs of the Future 29:715-720

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Committee for Proprietary Medicinal Products, "The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products," CPMP/986/96, December 17, 1997
		Detrol® package insert, Pharmacia & Upjohn Co., April, 2004
		Diokno et al., "Tolterodine (Detrol®) improves incontinence and nocturia in urological based study," 1999 April, J. Urol. 161 (4 Suppl):256, abstract 987
		Ekstrom et al., "Effects of tolterodine on bladder function in healthy volunteers," Journal of Urology 153(Suppl.):394A, abstract 662 from the 19 th Annual Meeting of the American Urological Association, Las Vegas, April 23-28, 1995
		Gardner & Altman, "Confidence intervals rather than P values: estimation rather than hypothesis testing," 1986, Br. Med. J. 292:746-750
		Gillberg et al., "Tolterodine, a new agent with tissue effect selectivity for urinary bladder," 1994, Neurourology and Urodynamics 13:435-436, abstract 60B from International Continence Society 24 th Annual Meeting, Prague, Czech Republic, August 1994
		Gillberg et al., "Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists," 1998, European Journal of Pharmacology 349: 285-292
		Hills et al., "Tolterodine," 1998, Drugs 55:813-820
		Jonas et al., "Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation," 1997, World J. Urol. 15:144-151
		Kang et al., "Cardiac ion channel effects of Tolterodine," 2004, J. Pharmacol. Exper. Thera. 308:935-940
		Kershen & Hsieh, "Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine," Curr. Urol. Rep. 5:359-367
		Klosa, "Eine Neue Synthesemethode der Darstellung von Diarylalkylaminen," 1966, Journal für Praktische Chemie 4:312-334 (in German) with English translation
		Klosa, "Eine Neue Synthese von Diphenylisopropylaminen," 1966, Journal für Praktische Chemie 4:335-340 (in German, with English translation)
		Larsson et al., "Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II safety and efficacy data," 1999, Urology 53: 990-998
		Lipinski, et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings" Elsevier Advanced Drug Delivery Reviews Vol. 23, pp. 3-25, 1997
		Millard et al., "Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity," 1999, J. Urol. 161:1551-1555
		Modiri et al., "Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats," 2002, Urology 59:963-968
		Naerger et al., "Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders," 1995, Neurourology and Urodynamics 14:524-526, abstract 76 from International Continence Society 25 th Annual Meeting, Sydney, Australia, October 1995
		Netzer, et al., "Screening lead compounds for QT interval prolongation" Drug Discovery Today Vol. 6, No. 2, pp.78-84, January 2001
		Nilsson et al., "Comparison of a 10 mg controlled release oxybutynin tablet with a 5 mg oxybutynin tablet in urge incontinence patients," 1997, Neurourol. Urodyn. 16:533-542
		Nilvebrant & Sparf, "Receptor binding profiles of some selective muscarinic antagonists," 1988, European Journal of Pharmacology 151:83-96
		Nilvebrant & Sparf, "Differences between Binding Affinities of some Antimuscarinic Drugs in the parotid Gland and those in the Urinary Bladder and Ileum" Acta Pharmacol. et toxicol. Vol. 53, No. 4, pp. 304-313, October 1983

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Nilvebrant et al., "The in vitro pharmacological profile of tolterodine – a new agent for the treatment of urinary urge incontinence," 1994, Neurourology and Urodynamics 13:433-435, abstract 60A from International Continence Society 24 th Annual Meeting, Prague, Czech Republic, August 1994
		Nilvebrant et al., "Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo," 1996, Neurourology and Urodynamics 15:310-311, abstract 34 from the 26th Annual Meeting of the International Continence Society, Athens, Greece, August 27-30, 1996
		Nilvebrant, "Tolterodine and terodiline – different pharmacological profiles," pages 141-142, abstract 181a, from the 27th Annual meeting of the International Continence Society, Yokohama, Japan, September 1997
		Nilvebrant et al "Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system," 2000, European Urology 37(Suppl. 2):84, abstract 333 from the XVth Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000
		Nilvebrant, "The mechanism of action of tolterodine," 2000, Reviews in Contemporary Pharmacotherapy 11:13-27
		Olsson et al., "Food increases the bioavailability of tolterodine but not effective exposure," 2001, J. Clin. Pharmacol. 41:298-304
		Olsson & Szamosi, "Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder," 2001, Clinical Pharmacokinetics 40:135-143
		Olsson & Szamosi, "Multiple dose pharmacokinetics of a new once daily extended release formulation versus immediate release tolterodine," 2001, Clinical Pharmacokinetics 40:227-235
		Pharmacology/Toxicology Review from Application Number 21-518, Center for Drug Evaluation and Research, pp. 1-3.
		Rentzhog et al., "Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study," 1998, Br. J. Urol. 81:42-48
		Roy, et al., "HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine" Circulation Vol. 94, No. 4, pp. 817-823, August 15, 1996
		Sachse et al., "Pharmacodynamics of multiple dose treatment with the novel antimuscarinic drug fesoterodine," 2002, Naunyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):413
		Sachse et al., "Safety and pharmacokinetics of the novel bladder-selective antimuscarinic drug fesoterodine in populations of different age or gender," 2002, Proceedings of the International Continence Society, 32:441
		Sachse et al., "Safety and pharmacokinetics of the novel bladder-selective antimuscarinic fesoterodine in populations of different ethnic origin," 2003, Proceedings of the International Continence Society, 33:377
		Sachse et al., "Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine," 2003, Naunyn-Schmiedeberg's Arch. Pharmacol. 367 (Suppl. 1):446
		Sachse et al., "Pharmacodynamics and pharmacokinetics of ascending multiple oral doses of the novel, bladder-selective antimuscarinic fesoterodine," 2003, Eur. Urol. Suppl 2:111
		Sachse et al., "Concomitant food intake does not significantly influence the pharmacokinetics of the novel, bladder-selective antimuscarinic fesoterodine," 2004, Proceedings of the International Continence Society, 34:580
		Sachse et al., "Safety, tolerability and pharmacokinetics of fesoterodine in patients with hepatic impairment," 2004, Proceedings of the International Continence Society, 34:585
		Sachse et al., "Safety, tolerability and pharmacokinetics of fesoterodine after co-treatment with the potent cytochrome P450 3A4 inhibitor ketoconazole," 2004, Proceedings of the International Continence Society, 34:586
		Sachse et al., "Clinical pharmacological aspects of the novel bladder-selective antimuscarinic fesoterodine," 2004, Progrès en Urologie, 14 (Suppl. 3):58
		Stahl et al., "Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity," 1995, Neurourol. Urodyn. 14:647-55

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Teuvo et al "Extended release tolterodine compared with immediate release tolterodine for the treatment of overactive bladder," 2000, European Urology 37(Suppl. 2):84, abstract 334 from the XVth Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000
		Van Kerrebroeck et al., "Tolterodine once daily: superior efficacy and tolerability in the treatment of the overactive bladder," 2001, Urology 57:414-421
		Van Kerrebroeck et al., "Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder," 1997, Neurourol. Urodyn. 16:478-479, abstract no. 91 from the 27th Annual meeting of the International Continence Society, Yokohama, Japan, September 1997
		Versi et al., "Dry mouth with conventional and controlled release oxybutynin in urinary incontinence," 2000, Obstet. Gynecol. 95:718-721
		Wefer et al., "Tolterodine: an overview," 2001, World Journal of Urology 19:312-318

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	